A vaccine which could "revolutionise" tuberculosis treatment has been unveiled by researchers.
A chest x-ray showing alveolar infiltration at both lung due to mycobacterium tuberculosis infection. Photo: 123RF
It is hoped the vaccine will provide long-term protection against the disease, which kills 1.5 million people around the world each year.
The highly contagious disease is caused by bacteria, and the current vaccine, the BCG jab, is not very effective.
However, while initial trials have proved successful, the vaccine is still a few years away from being licensed.
The team of researchers, who come from all over the world, revealed the vaccine, which is made up of proteins from bacteria which trigger an immune response, during a global summit on lung health in the southern Indian city of Hyderabad on Tuesday.
It has already cleared a critical phase of clinical trials and been tested on more than 3,500 adults in TB endemic regions of South Africa, Kenya and Zambia, researchers said.
Why is the vaccine "revolutionary"?
David Lewinsohn, a TB expert, told the BBC the potential vaccine was a "real game changer".
"What is really remarkable is that it was effective in adults who were already infected with Mycobacterium tuberculosis that is the causative agent of TB," he said.
"As most people who are infected with Mycobacterium tuberculosis do not get TB, we have believed that infection confers some degree of protection. As a result it is really exciting that a vaccine has been shown to improve on this natural immunity."
Dr Lewinsohn said the new vaccine had cleared a key "mid-phase development, and it is designed to test both safety and to provide an early indicator of efficacy".
"It is likely that the vaccine will need to be tested in additional populations, and possibly bigger trials before it will be licensed. Assuming the data holds up in the remaining trials, which seems likely, this vaccine has the potential to revolutionise TB treatment."
How long will it take for the vaccine to reach the market?
Dr Lewinsohn estimates that, if if all goes well, the vaccine should reach people who most need it by about 2028.
Researchers say proving that the vaccine works often requires studies that are much larger than required for viral diseases such as measles. Drug firm GlaxoSmithKline (GSK) has been working on the TB vaccine for nearly 20 years.
To progress, a vaccine must show efficacy in animals, usually mice, but also guinea pigs and non-human primates.
One reason developing a TB vaccine is a challenge, say researchers, is that "animal models often do not reflect what we would like to see in an effective vaccine".
For example, in the mouse, TB tends to be an "indolent disease" and researchers might define success as a roughly 10-fold reduction in the number of bacteria in the lung.
This is encouraging, but a child with a tenth of the bacteria still has TB.
How serious is the current situation?
In 2018 an estimated 10 million people fell ill with TB, according to the World Health Organization (WHO).
Nearly a quarter of the world's population has latent TB infection. This means they carry the bacteria in an inactive form, are not ill and do not transmit the disease to others. People with latent TB have a 5 to 10 percent risk in their lifetimes of developing active TB.
Meanwhile, multi-drug resistant tuberculosis (MDR-TB) - a type of tuberculosis which is unresponsive or resistant to at least two of the first line of anti-TB drugs - continues to be a major public health threat. Drug-resistant TB is harder and more expensive to diagnose and treat.
The WHO aims to reduce the number of new TB cases by 90 percent and number of TB deaths by 95 percent between 2015 and 2035.
- BBC
